Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Plus Induction Chemotherapy Followed by CCRT for Locally Advanced Cervical Cancer
NCT06511726Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2024
- Primary completion
- Nov 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in Cervical Cancer (CC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Objective Response Rate at 18 months. Started Jan 2024; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06511726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06511726.